Presenting features
| . | De novo MDS/AML, n = 960 (%) . | tMDS/tAML, n = 24 (%) . | P . |
|---|---|---|---|
| Age, y | .02 | ||
| 0-2 | 196 (20) | 0 (0) | |
| 3-10 | 385 (40) | 10 (42) | |
| 11-21 | 379 (40) | 14 (58) | |
| Sex | .10 | ||
| Male | 498 (52) | 17 (71) | |
| Female | 462 (48) | 7 (29) | |
| Race | .38 | ||
| White | 650 (68) | 14 (58) | |
| Nonwhite | 310 (32) | 10 (42) | |
| White blood count, × 109/L | .01 | ||
| Median | 20.05 | 5.5 | |
| Range | 0.5-644.4 | 1.1-285 | |
| Platelets, × 109/L | .38 | ||
| Median | 53 | 39 | |
| Range | 1-547 | 4-214 | |
| Hemoglobin, g/L | .13 | ||
| Median | 82 | 92 | |
| Range | 27-160 | 37-134 | |
| Chloroma | 83 (9) | 0 (0) | .26 |
| CNS involvement at diagnosis | 83 (9) | 0 (0) | .26 |
| Splenomegaly | 398 (42) | 4 (17) | .03 |
| Hepatomegaly | 387 (40) | 4 (17) | .02 |
| Hepatosplenomegaly | 304 (32) | 2 (9) | .02 |
| Lymphadenopathy | 438 (46) | 7 (29) | .15 |
| FAB | .04 | ||
| M0 | 30 (3) | 0 (0) | 1.00 |
| M1/M2 | 392 (42) | 5 (21) | .06 |
| M3* | 50 (5) | 0 (0) | .63 |
| M4/M5 | 328 (35) | 12 (50) | .13 |
| M6 | 20 (2) | 1 (4) | .42 |
| M7 | 54 (6) | 1 (4) | 1.00 |
| MDS | 62 (7) | 5 (21) | .02 |
| . | De novo MDS/AML, n = 960 (%) . | tMDS/tAML, n = 24 (%) . | P . |
|---|---|---|---|
| Age, y | .02 | ||
| 0-2 | 196 (20) | 0 (0) | |
| 3-10 | 385 (40) | 10 (42) | |
| 11-21 | 379 (40) | 14 (58) | |
| Sex | .10 | ||
| Male | 498 (52) | 17 (71) | |
| Female | 462 (48) | 7 (29) | |
| Race | .38 | ||
| White | 650 (68) | 14 (58) | |
| Nonwhite | 310 (32) | 10 (42) | |
| White blood count, × 109/L | .01 | ||
| Median | 20.05 | 5.5 | |
| Range | 0.5-644.4 | 1.1-285 | |
| Platelets, × 109/L | .38 | ||
| Median | 53 | 39 | |
| Range | 1-547 | 4-214 | |
| Hemoglobin, g/L | .13 | ||
| Median | 82 | 92 | |
| Range | 27-160 | 37-134 | |
| Chloroma | 83 (9) | 0 (0) | .26 |
| CNS involvement at diagnosis | 83 (9) | 0 (0) | .26 |
| Splenomegaly | 398 (42) | 4 (17) | .03 |
| Hepatomegaly | 387 (40) | 4 (17) | .02 |
| Hepatosplenomegaly | 304 (32) | 2 (9) | .02 |
| Lymphadenopathy | 438 (46) | 7 (29) | .15 |
| FAB | .04 | ||
| M0 | 30 (3) | 0 (0) | 1.00 |
| M1/M2 | 392 (42) | 5 (21) | .06 |
| M3* | 50 (5) | 0 (0) | .63 |
| M4/M5 | 328 (35) | 12 (50) | .13 |
| M6 | 20 (2) | 1 (4) | .42 |
| M7 | 54 (6) | 1 (4) | 1.00 |
| MDS | 62 (7) | 5 (21) | .02 |
During the course of this study, patients with FAB M3 became eligible for treatment with trans-retinoic acid on the Intergroup Study CCG 2911.